Abstract
Background: Pilocarpine hydrochloride is commonly prescribed to patients with dry mouth and eye using a frequent dosing schedule. The aim of this study was to evaluate the sustained effects of this highly soluble drug carried by a gelatin hydrogel, which was administered by an implant mediated drug delivery system (IMDDS).
Methods: The IMDDS was installed in a total of 24 rabbits. After complete healing, pilocarpine hydrochloride was administered as 30 mg as raw powder (Group 1; n = 8), 30 mg in gelatin hydrogel (Group 2; n = 8), and 60 mg in gelatin hydrogel (Group 3; n = 8). The effects were evaluated by tear volume measured using the Schirmer tear test for 2 weeks after administration. Results: All 3 groups showed an increase in tear volume from the initial measurement at 1 hour. Group 1 exhibited this increase for 24 hours, while Groups 2 and 3 sustained this increase for 5 days and 7.5 days, respectively. Conclusion: When provided in gelatin hydrogel, highly water-soluble pilocarpine hydrochloride administered through IMDDS resulted in sustained effects with increased tear volume in normal rabbits.Keywords: Dry eye, hydrogel, implant-mediated drug delivery system, osseogate, pilocarpine hydrochloride, sustained release.
Current Drug Delivery
Title:The Sustained Effects on Tear Volume of Pilocarpine Hydrochloride in Gelatin by Hydrogel Administered by An Implant-mediated Drug Delivery System
Volume: 14 Issue: 4
Author(s): Seunghee Cha, Hong-Kyun Kim, Hong-Seop Kho and Young-Seok Park*
Affiliation:
- Department of Oral Anatomy, Seoul National University School of Dentistry, P.O. Box: 03080, Seoul,Korea
Keywords: Dry eye, hydrogel, implant-mediated drug delivery system, osseogate, pilocarpine hydrochloride, sustained release.
Abstract: Background: Pilocarpine hydrochloride is commonly prescribed to patients with dry mouth and eye using a frequent dosing schedule. The aim of this study was to evaluate the sustained effects of this highly soluble drug carried by a gelatin hydrogel, which was administered by an implant mediated drug delivery system (IMDDS).
Methods: The IMDDS was installed in a total of 24 rabbits. After complete healing, pilocarpine hydrochloride was administered as 30 mg as raw powder (Group 1; n = 8), 30 mg in gelatin hydrogel (Group 2; n = 8), and 60 mg in gelatin hydrogel (Group 3; n = 8). The effects were evaluated by tear volume measured using the Schirmer tear test for 2 weeks after administration. Results: All 3 groups showed an increase in tear volume from the initial measurement at 1 hour. Group 1 exhibited this increase for 24 hours, while Groups 2 and 3 sustained this increase for 5 days and 7.5 days, respectively. Conclusion: When provided in gelatin hydrogel, highly water-soluble pilocarpine hydrochloride administered through IMDDS resulted in sustained effects with increased tear volume in normal rabbits.Export Options
About this article
Cite this article as:
Cha Seunghee, Kim Hong-Kyun, Kho Hong-Seop and Park Young-Seok*, The Sustained Effects on Tear Volume of Pilocarpine Hydrochloride in Gelatin by Hydrogel Administered by An Implant-mediated Drug Delivery System, Current Drug Delivery 2017; 14 (4) . https://dx.doi.org/10.2174/1567201813666161013150648
DOI https://dx.doi.org/10.2174/1567201813666161013150648 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Why Anticancer Nanomedicine Needs Sugars?
Current Medicinal Chemistry DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design 5-HT7 Receptors
Current Drug Targets - CNS & Neurological Disorders Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Voltage-Gated Sodium Channels and Pain
Current Drug Targets - CNS & Neurological Disorders Aminoalkylpyridines (AAPs), Triazoline Metabolite Analogues, As Anticonvulsants Highly Effective in the Mes Test
Current Medicinal Chemistry